Top News

Covid-19 pandemic slows down clinical trials, initially in China, now in Europe and US. Companies consider resuming trials in Asia & China as outbreak seemingly under control. Government issues guidance to industry


Karen Weintraub


Related: US FDA, Fierce Biotech, @DrWoodcockFDA, @SteveFDA, European Medicines Agency (EMA), @pareras, MHRA (UK gov), STAT

Johnson & Johnson CEO announces choosing a lead vaccine candidate for Covid-19. Human study to start in September 2020, may be ready for emergency use by early 2021


William Feuer


As US became the epicenter of the pandemic, experts question the supply-driven policy of dissuading people to wear masks. Some believe this is a mistake and missed opportunity


Kelly Servick


Related: @BioBreakout, @Benioff, Medscape, @FaceTheNation, @jeremyphoward, @adamcchang, @SGottliebFDA, @SenToomey, @lexfridman, New York Times, U.S. Surgeon General, The BMJ

Social distancing: MIT study shows 23 to 27 feet is needed for Covid-19 protection, 4 times longer than CDC guideline of 6-foot human separation, 8 times longer than WHO recommendation of 3-foot separation

Potential Implications for Reducing Transmission of COVID-19


Lydia Bourouiba

JAMA-Journal of American Medical Association

Related: @Carnage4Life, The Telegraph - London, @davidcnorrismd, @ehlJAMA, EPIDEMIC with Dr. Celine Gounder and Ronald Klain

Overwhelmed by demand for its promising Covid19 drug Remdesivir , Gilead paused emergency access to switch to a broader access program. The drug received FDA orphan drug status

The company says it will switch to a broader approach for its experimental drug, remdesivir. But it was overwhelmed by demand for a potential treatment promoted by President Trump


Katie Thomas

New York Times

Related: US FDA, @AlecGaffney, MarketWatch, STAT

Loss of sense of smell, sometimes taste, reported as an early sign of coronavirus infection, even without other symptoms


Adam Bienkov

Business Insider

Related: @JoyceWhiteVance, @rudygobert27, New York Times, @jaketapper, ENT UK, @NadineDorries

Neil Ferguson & Imperial College London grim report on virus made UK to abandon 'Herd Immunity' policy and US to take drastic action

It wasn’t so much the numbers themselves, frightening though they were, as who reported them: Imperial College London


Mark Landler

New York Times

Related: The Daily Beast, @neil_ferguson, The Washington Post, Financial Times, @MarkLandler

Ex-FDA Commissioners laid out future road map for effective response to threat like COVID-19. Experts chipped with advice


Scott Gottlieb

Duke-Margolis Center for Health Policy

Related: @drfeifei, @EricTopol, @SGottliebFDA

Gilead's remdesivir may have helped 14 elderly and critically ill Americans to live who had contracted Covid-19 from Diamond Princess cruise ship. Other cases of seemingly efficacy also reported. Raise high hope for this medicine



Investor's Business Daily

Related: @WSJ, @paulsperry_, @sciencecohen, Science, @Chenbariatrics1, @CMichaelGibson, Wall Street Journal

Biotech Regeneron is developing a two-pronged drug to fight Covid-19: a 'passive-vaccine' antibody to prevent infection, or, antibody treatment for infected people at higher dose. The Company has succeeded for Ebola virus using the same technology

"We are optimistic, because we've done this approach to treat many human diseases," the company's CEO says


Jay Blackman


Related: Westfaironline, CNBC, NASDAQ

70 of the 92 coronavirus infections in Massachusetts linked to biotech company Biogen's leadership conference in Boston. Cascade cases also spread to in other states and countries

primary article image


Mark Arsenault

Boston Globe

Related: CNN, @BioTurboNick, @AndyBiotech

AstraZeneca's major phase III bladder cancer trial of Imfinzi failed to show survival benefit vs. standard-of-care. This study was a commitment to FDA following an accelerated approval. Other studies of Imfinzi in bladder cancer still ongoing


Lisa Astor

Targeted Oncology

Related: Endpoints News

Editas and Allergan test CRISPR / gene editing therapy in patient for treating blindness, first time gene-editing occurs in patient's body, while most gene-editing drugs take effect on ex vivo basis (outside of body)

primary article image


Mark Prvulovic


Related: @EricTopol, New York Times, BioPharma Dive

Biotech firms Alnylam and Vir expand partnership to develop RNA interference tech-based therapy for coronavirus. RNAi aims to silence messenger RNA that encodes for disease-causing proteins


Staff Writer

Seeking Alpha

Related: Genetic Engineering & Biotechnology News

French pharma giant Sanofi's "return to oncology" with FDA approval of Sarclisa for treating multiple myeloma. The company backing away from its traditional diabetes & cardiovascular areas


John Carroll

Endpoints News

Related: US FDA, @theMMRF, FiercePharma

Shareholder group of J&J calls for split of Alex Gorsky's dual CEO and chairman roles


Eric Sagonowsky


Related: New York Times

Facing coronavirus pandemic, biotech / pharma companies, academia, and government team up and race to develop cure and vaccines


Robert Schroeder


Related: Clinical Trials Arena, STAT

Biotech trade group BIO appointed the CEO of Vir Biotechnology George Scangos to coordinate biotech industry's response and efforts to COVID-19. Vir was the first biotech firm to start treatment development since the outbreak started

primary article image


Amber Tong

Endpoints News

AbbVie's blood cancer drug Venclexta failed to show survival benefit in a phase III leukemia study, conditionally approved by FDA previously. Another similar phase III study of Venclexta by AbbVie is ongoing


Zacks Equity Research


Gilead to buy cancer drug biotech Forty Seven for $4.9 billion to control its anti-CD47 antibody magrolimab and start presence in immuno-oncology area

primary article image


Nick Taylor

Fierce Biotech

Related: Wall Street Journal

Latest News

FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic

02 Apr 2020, Staff Writer, US FDA

CRISPR Therapeutics braces for 'severe impact' from COVID-19 crisis

01 Apr 2020, 9:12 PM, Ben Adams, Fierce Biotech

COVID-19 Slows Drug Studies, Curbs Clinical Trials

31 Mar 2020, 8:42 PM, Karen Weintraub, Medscape

Johnson & Johnson says human testing of its coronavirus vaccine to begin by September

30 Mar 2020, 5:31 PM, William Feuer, CNBC

'Stealth Transmission' of COVID-19 Demands Widespread Mask Usage

29 Mar 2020, 8:21 PM, Eldad Einav, Medscape

Would everyone wearing face masks help us slow the pandemic?

28 Mar 2020, 7:02 PM, Kelly Servick, Science

Guidance on the Management of Clinical Trials during the COVID-19 (Coronavirus) pandemic

27 Mar 2020, 9:32 PM, Staff Writer, European Medicines Agency (EMA)

More Americans Should Probably Wear Masks for Protection

27 Mar 2020, 7:06 PM, Knvul Sheikh, New York Times

Social distancing: new study suggests two metres is not enough

27 Mar 2020, 4:54 PM, Sarah Knapton, The Telegraph - London

Turbulent Gas Clouds and Respiratory Pathogen Emissions

26 Mar 2020, 4:07 PM, Lydia Bourouiba, JAMA-Journal of American Medical Association

Search Orphan Drug Designations and Approvals

23 Mar 2020, 9:46 PM, Staff Writer, US FDA

Gilead Sciences, 'flooded' by demand for remdesivir, halts compassionate use

23 Mar 2020, 9:35 PM, Jaimy Lee, MarketWatch

Coronavirus Patients in Limbo as Gilead Suspends Emergency Drug Access

23 Mar 2020, 9:23 PM, Katie Thomas, New York Times

As Covid-19 spreads, disruptions to clinical trial and drug development accelerate

23 Mar 2020, 9:00 PM, ADAM FEUERSTEIN, STAT

Gilead pauses access to experimental Covid-19 drug due to ‘overwhelming demand’

22 Mar 2020, 9:31 PM, Matthew Herper, STAT

Lost Sense of Smell May Be Peculiar Clue to Coronavirus Infection

22 Mar 2020, 6:29 PM, Roni Rabin, New York Times

If you've lost your sense of smell or taste, you could be a 'hidden carrier' of the coronavirus

22 Mar 2020, 6:13 PM, Adam Bienkov, Business Insider

Loss of sense of smell as marker of COVID-19 infection

21 Mar 2020, 6:24 PM, Prof Claire Hopkins, ENT UK

BONUS / A False Dichotomy: Airborne versus Droplet / Roxanne Khamsi and Lydia Bourouiba

20 Mar 2020, 4:43 PM, Celine Gounder, EPIDEMIC with Dr. Celine Gounder and Ronald Klain

Advancing Treatments to Save Lives and Reduce the Risk of COVID-19

20 Mar 2020, 3:07 AM, Scott Gottlieb, Duke-Margolis Center for Health Policy